Fidelity Investments’s Clearside Biomedical CLSD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-83
Closed -$330 5453
2025
Q3
$330 Buy
+83
New +$565 ﹤0.01% 5119
2023
Q3
Sell
-129
Closed -$2.17K 5307
2023
Q2
$2.17K Sell
129
-548
-81% -$9.43K ﹤0.01% 4567
2023
Q1
$10.6K Buy
677
+524
+342% +$10.2K ﹤0.01% 4107
2022
Q4
$2.57K Buy
153
+80
+110% +$1.44K ﹤0.01% 4451
2022
Q3
$1K Buy
+73
New +$1.6K ﹤0.01% 4638
2022
Q1
Sell
-8
Closed 5007
2021
Q4
$0 Sell
8
-1
-11% -$65 ﹤0.01% 4393
2021
Q3
$1K Buy
+9
New +$794 ﹤0.01% 4107
2019
Q1
Sell
-55
Closed -$1K 3659
2018
Q4
$1K Sell
55
-11,720
-100% -$550K ﹤0.01% 3381
2018
Q3
$1.09M Sell
11,775
-5,619
-32% -$668K ﹤0.01% 2466
2018
Q2
$2.79M Sell
17,394
-6,612
-28% -$1.11M ﹤0.01% 2282
2018
Q1
$3.86M Sell
24,006
-11,624
-33% -$1.42M ﹤0.01% 2243
2017
Q4
$3.74M Sell
35,630
-29,783
-46% -$3.2M ﹤0.01% 2231
2017
Q3
$8.58M Sell
65,413
-6
-0% -$733 ﹤0.01% 1996
2017
Q2
$8.94M Buy
65,419
+6,146
+10% +$738K ﹤0.01% 1981
2017
Q1
$7.06M Sell
59,273
-9,367
-14% -$1.11M ﹤0.01% 2081
2016
Q4
$9.21M Buy
68,640
+54,259
+377% +$13.6M ﹤0.01% 2003
2016
Q3
$3.74M Buy
+14,381
New +$1.76M ﹤0.01% 2256

Other funds holding CLSD

Fidelity Investments's CLSD Position: Q4 2025 in Review

Fidelity Investments sold out of Clearside Biomedical (CLSD) in Q4 2025, closing a stake of 83 shares — an estimated $330 sold.

Fidelity Investments first reported a position in CLSD in Q3 2016 and held it in 17 quarters. The position peaked at $9.21M in Q4 2016. 1 fund tracked by Wall St. Rank holds CLSD as of Q4 2025.

  • Fidelity Investments reported no remaining Clearside Biomedical position as of Q4 2025 after selling out during the quarter.
  • Fidelity Investments sold 83 Clearside Biomedical shares in Q4 2025, an estimated $330.
  • Fidelity Investments first reported a position in Clearside Biomedical in Q3 2016 and held it in 17 quarters.
  • Fidelity Investments's Clearside Biomedical position peaked at $9.21M in Q4 2016.
  • 1 fund tracked by Wall St. Rank held Clearside Biomedical as of Q4 2025.

Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.